ML1419c Peptide Immunization Induces Mycobacterium Leprae-specific HLA-A*0201-restricted CTL in Vivo with Potential to Kill Live Mycobacteria
Overview
Authors
Affiliations
MHC class I-restricted CD8(+) T cells play an important role in protective immunity against mycobacteria. Previously, we showed that p113-121, derived from Mycobacterium leprae protein ML1419c, induced significant IFN-γ production by CD8(+) T cells in 90% of paucibacillary leprosy patients and in 80% of multibacillary patients' contacts, demonstrating induction of M. leprae-specific CD8(+) T cell immunity. In this work, we studied the in vivo role and functional profile of ML1419c p113-121-induced T cells in HLA-A*0201 transgenic mice. Immunization with 9mer or 30mer covering the p113-121 sequence combined with TLR9 agonist CpG induced HLA-A*0201-restricted, M. leprae-specific CD8(+) T cells as visualized by p113-121/HLA-A*0201 tetramers. Most CD8(+) T cells produced IFN-γ, but distinct IFN-γ(+)/TNF-α(+) populations were detected simultaneously with significant secretion of CXCL10/IFN-γ-induced protein 10, CXCL9/MIG, and VEGF. Strikingly, peptide immunization also induced high ML1419c-specific IgG levels, strongly suggesting that peptide-specific CD8(+) T cells provide help to B cells in vivo, as CD4(+) T cells were undetectable. An additional important characteristic of p113-121-specific CD8(+) T cells was their capacity for in vivo killing of p113-121-labeled, HLA-A*0201(+) splenocytes. The cytotoxic function of p113-121/HLA-A*0201-specific CD8(+) T cells extended into direct killing of splenocytes infected with live Mycobacterium smegmatis expressing ML1419c: both 9mer and 30mer induced CD8(+) T cells that reduced the number of ML1419c-expressing mycobacteria by 95%, whereas no reduction occurred using wild-type M. smegmatis. These data, combined with previous observations in Brazilian cohorts, show that ML1419c p113-121 induces potent CD8(+) T cells that provide protective immunity against M. leprae and B cell help for induction of specific IgG, suggesting its potential use in diagnostics and as a subunit (vaccine) for M. leprae infection.
Coppola M, van den Eeden S, Robbins N, Wilson L, Franken K, Adams L Front Immunol. 2018; 9:308.
PMID: 29535713 PMC: 5834475. DOI: 10.3389/fimmu.2018.00308.
Diguanylate cyclase activity of the Mycobacterium leprae T cell antigen ML1419c.
Rotcheewaphan S, Belisle J, Webb K, Kim H, Spencer J, Borlee B Microbiology (Reading). 2016; 162(9):1651-1661.
PMID: 27450520 PMC: 5772806. DOI: 10.1099/mic.0.000339.
Coppola M, van den Eeden S, Wilson L, Franken K, Ottenhoff T, Geluk A Clin Vaccine Immunol. 2015; 22(9):1060-9.
PMID: 26202436 PMC: 4550671. DOI: 10.1128/CVI.00271-15.
Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A PLoS One. 2014; 9(10):e108848.
PMID: 25310094 PMC: 4195657. DOI: 10.1371/journal.pone.0108848.